




The relative strengths and weaknesses of Progenics Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Progenics Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Progenics Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 41% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	96,870
Cost of Goods Sold	0
Intangible Assets	43,443
Liabilities, Current	15,359
Liabilities, Non-Current	48,770
Other Assets	1,522
Other Compr. Net Income	52
Other Expenses	-9,072
Other Liabilities	18,375
Other Net Income	-4,285
Other Revenues	11,698
Property and Equipment	4,122
Research and Development	42,589
Selling, General and Administrative Expense	24,909

Output Variable	Value in 1000 USD
Assets	145,957
Liabilities	82,504
Expenses	58,426
Revenues	11,698
Stockholders Equity	63,453
Net Income	-51,013
Comprehensive Net Income	-50,987
BaseVar	151,461
ECR before LimitedLiability	76%
Economic Capital Ratio	211%